2B78:XETRA:XETRA-iShares Healthcare Innovation UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 7.172

Change

-0.03 (-0.43)%

Market Cap

USD 1.14B

Volume

0.03M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-27 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.80 (+1.61%)

USD 502.95B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.26 (+1.62%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.39 (+1.50%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.42 (+1.54%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.52 (+2.21%)

USD 157.79B
8R80:XETRA Amundi Index Solutions - Amund..

+2.84 (+2.08%)

USD 102.11B
JARI:XETRA Amundi Index Solutions - Amund..

+0.62 (+1.35%)

USD 102.11B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.78 (+1.59%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+10.98 (+2.10%)

USD 80.38B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

+0.39 (+1.75%)

USD 79.79B

ETFs Containing 2B78:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.18% 47% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.18% 47% F 49% F
Trailing 12 Months  
Capital Gain 6.73% 40% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.73% 39% F 43% F
Trailing 5 Years  
Capital Gain 33.61% 51% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.61% 49% F 51% F
Average Annual (5 Year Horizon)  
Capital Gain 4.96% 51% F 51% F
Dividend Return 4.96% 50% F 49% F
Total Return N/A 1% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 21.93% 16% F 28% F
Risk Adjusted Return 22.60% 36% F 38% F
Market Capitalization 1.14B 80% B- 70% C-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.